1. Home
  2. IQ vs WVE Comparison

IQ vs WVE Comparison

Compare IQ & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iQIYI Inc.

IQ

iQIYI Inc.

HOLD

Current Price

$1.23

Market Cap

1.0B

ML Signal

HOLD

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$5.71

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IQ
WVE
Founded
2009
2012
Country
China
Singapore
Employees
N/A
N/A
Industry
Consumer Electronics/Video Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
IQ
WVE
Price
$1.23
$5.71
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
16
Target Price
$2.91
$29.81
AVG Volume (30 Days)
6.7M
3.1M
Earning Date
05-18-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$3,704,000.00
Revenue This Year
$0.28
N/A
Revenue Next Year
$3.54
$85.67
P/E Ratio
N/A
N/A
Revenue Growth
N/A
149.43
52 Week Low
$0.95
$5.02
52 Week High
$2.76
$21.73

Technical Indicators

Market Signals
Indicator
IQ
WVE
Relative Strength Index (RSI) 63.52 40.70
Support Level $1.20 $5.48
Resistance Level $1.26 $6.48
Average True Range (ATR) 0.06 0.27
MACD 0.02 -0.03
Stochastic Oscillator 89.58 13.92

Price Performance

Historical Comparison
IQ
WVE

About IQ iQIYI Inc.

Iqiyi is a leading streaming video-on-demand company in China that generates revenue mostly through a subscription basis. The platform also provides user-generated content to nonpaying users, monetized through ads. The company self-produces much of the subscription content and also generates revenue through content distribution, gaming, and IP licensing. Iqiyi competes directly with Tencent Video, Alibaba's Youku, ByteDance's MangoTV, and Bilibili. The company is 45% and 5% owned by Baidu and Xiaomi, respectively.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: